Greenwich LifeSciences, Inc. (GLSI)

Market Cap	144.91M
Revenue (ttm)	n/a
Net Income (ttm)	-16.57M
Shares Out	13.37M
EPS (ttm)	-1.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,219
Open	11.22
Previous Close	11.22
Day's Range	10.75 - 11.52
52-Week Range	8.06 - 17.00
Beta	3.15
Analysts	Strong Buy
Price Target	39.00 (+259.78%)
Earnings Date	Aug 13, 2025

About GLSI

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 25, 2020
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: GLSI
• Website: https://greenwichlifesciences.com

Analyst Summary

According to one analyst, the rating for GLSI stock is "Strong Buy" and the 12-month stock price target is $39.0.

Price Target

$39.0

(259.78% upside)

Analyst Consensus: Strong Buy